 Small, uncontrolled studies with intravitreal injection into the vitreous space of the eye bevacizumab Avastin suggest that this agent enhances clearance of diabetic vitreous haemorrhage1,2,3. Bevacizumab is a monoclonal antibody licensed for the treatment of metastatic cancer. It works by inhibiting vascular endothelial growth factor VEGF, a chemical mediator that promotes new blood vessel growth within tumours. It has been used off-label without a licenceto treat neovascular age-related macular degeneration nAMD - a common eye disease with loss of vision, and other conditions characterised by intraocular new blood vessel growth neovascularisation. 